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Heparan sulfate 3-O-sulfotransferase transfers sulfate
to the 3-OH position of a glucosamine residue of heparan
sulfate (HS) to form 3-O-sulfated HS. The 3-O-sulfated
glucosamine residue contributes to two important bio-
logical functions of HS: binding to antithrombin and
thereby carrying anticoagulant activity, and binding to
herpes simplex viral envelope glycoprotein D to serve as
an entry receptor for herpes simplex virus 1. A total of
five HS 3-O-sulfotransferase isoforms were reported
previously. Here we report the isolation and character-
ization of a novel HS 3-O-sulfotransferase isoform, des-
ignated as HS 3-O-sulfotransferase isoform 5 (3-OST-5).
3-OST-5 cDNA was isolated from a human placenta
cDNA library and expressed in COS-7 cells. The disac-
charide analysis of 3-OST-5-modified HS revealed that
3-OST-5 generated at least three 3-O-sulfated disaccha-
rides as follows: IdoUA2S-AnMan3S, GlcUA-AnMan3S6S,
and IdoUA2S-AnMan3S6S. Transfection of the plasmid
expressing 3-OST-5 rendered wild type Chinese hamster
ovary cells susceptible to the infection by herpes sim-
plex virus 1, suggesting that 3-OST-5-modified HS serves
as an entry receptor for herpes simplex virus 1. In addi-
tion, 3-OST-5-modified HS bound to herpes simplex viral
envelope protein glycoprotein D. Furthermore, we
found that 3-OST-5-modified HS also bound to anti-
thrombin, suggesting that 3-OST-5 also produces antico-
agulant HS. In summary, our results indicate that a new
member of 3-OST family generates both anticoagulant
HS and an entry receptor for herpes simplex virus 1.
These results provide a new insight regarding the mech-
anism for the biosynthesis of biologically active HS.
Heparan sulfates (HSs)1 are highly sulfated polysaccharides,
present on the surface of mammalian cells and in the extracel-
lular matrix in large quantities. HSs play critical roles in a
variety of important biological processes, including assisting
viral infection, regulating blood coagulation and embryonic
development, suppressing tumor growth, and controlling the
eating behavior of mice by interacting with specific regulatory
proteins (1–5). HS polysaccharides carry negative charges un-
der physiological pH, and the disaccharide repeating units
consist of 134-linked sulfated glucosamine and uronic acid.
The unique sequences determine to which specific proteins HSs
bind, thereby regulating biological processes.
The biosynthesis of HS occurs in the Golgi apparatus. It is
initially synthesized as a copolymer of glucuronic acid and
N-acetylated glucosamine by D-glucuronyl and N-acetyl-D-glu-
cosaminyltransferase, followed by various modifications (6).
These modifications include N-deacetylation and N-sulfation of
glucosamine, C5 epimerization of glucuronic acid to form idu-
ronic acid residues, 2-O-sulfation of iduronic and glucuronic
acid, as well as 6-O-sulfation and 3-O-sulfation of glucosamine.
Several enzymes that are responsible for the biosynthesis of HS
have been cloned and characterized (see review by Esko and
Lindahl (7). These enzymes have become essential tools for
investigating the relationship between the structures and func-
tions of HS.
What is still unknown is the detailed mechanism for regu-
lating the biosynthesis of HS with a defined saccharide se-
quence. A recent report (8) suggests that the expression levels
of various HS biosynthetic enzyme isoforms contribute to the
synthesis of specific saccharide sequences in specific tissues.
HS N-deacetylase/N-sulfotransferase, 3-O-sulfotransferase,
and 6-O-sulfotransferase are present in multiple isoforms.
Each isoform is believed to recognize a saccharide sequence
around the modification site in order to generate a specific
sulfated saccharide sequence (8–10). For instance, HS D-glu-
cosaminyl 3-O-sulfotransferase (3-OST) isoforms generate 3-O-
sulfated glucosamine residues that are linked to different sul-
fated uronic acid residues. 3-OST-1 transfers sulfate to the
3-OH position of an N-sulfated glucosamine residue that is
linked to a glucuronic acid residue at the nonreducing end
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(GlcUA-GlcNS6S). However, 3-OST-3 transfers sulfate to the
3-OH position of an N-unsubstituted glucosamine residue that
is linked to a 2-O-sulfated iduronic acid at the nonreducing end
(IdoUA2S-GlcNH26S) (11). The difference in the substrate
specificity of 3-OSTs results in distinct biological functions. For
example, the HS modified by 3-OST-1 binds to antithrombin
(AT) and has anticoagulant activity (12). However, the HS
modified by 3-OST-3 (3-OST-3A and 3-OST-3B)2 binds to gly-
coprotein D (gD) of herpes simplex virus, type 1, thus mediat-
ing viral entry (13).
The HS- and heparin-regulated anticoagulation mechanisms
have been studied extensively. It is now known that HS and
heparin interact with AT, a serine protease inhibitor, to inhibit
the activities of thrombin and factor Xa in the blood coagulation
cascade (2). Anticoagulant-active HS (HSact) and heparin con-
tain one or multiple AT-binding sites per polysaccharide chain.
This binding site contains a specific pentasaccharide sequence
with a structure of GlcNS(or Ac)6S-GlcUA-GlcNS3S(6S)-
IdoUA2S-GlcNS6S-. The 3-O-sulfation of glucosamine for gen-
erating GlcNS3S(6S) residue, which is carried out by 3-OST-1
(EC 2.8.2.23), is the critical modification for the synthesis of
HSact (12, 14).
Cell surface HS assists herpes simplex viral infection (15). A
recent report (13) suggests that a specific 3-O-sulfated HS is
involved in assisting HSV-1 entry. The 3-O-sulfated HS is
generated by 3-OST-3 but not by 3-OST-1. In addition, the
3-O-sulfated HS provides binding sites for HSV-1 envelope
glycoprotein D, which is a key viral protein involved in the
entry of HSV-1 (13). Because 3-OST-3-modified HS is rarely
found in HS from natural sources, the study suggests that
HSV-1 recognizes a unique saccharide structure. Indeed, the
result from the structural characterization of a gD-binding
octasaccharide revealed that the octasaccharide possesses a
specific saccharide sequence (16). In addition, the binding af-
finity of the 3-O-sulfated HS for gD is about 2 M (13). This
affinity is similar to that reported for the binding of gD to the
protein receptors, suggesting that HSV-1 utilizes both protein
and HS cell surface receptors to infect target cells (17, 18). It is
believed that the interaction between gD and the 3-O-sulfated
HS or the protein entry receptors somehow triggers the fusion
between the virus and the cell in the presence of other viral
envelope proteins, including gB, gH, and gL (19). A study of the
co-crystal structure of gD and herpes entry receptor HveA
suggests that the binding of HveA to gD induces conforma-
tional changes in gD (20).
It is known that the enzymes for synthesizing HSact and an
entry receptor for HSV-1 belong to two 3-OST isoforms. These
two isoforms generate the 3-O-sulfated glucosamine residue
located in different saccharide sequences as described above. In
this article, we report that a 3-OST homologous protein, desig-
nated as HS 3-O-sulfotransferase isoform-5 (3-OST-5), pos-
sesses the activities for generating both HSact and HSV-1 entry
receptor (or gD-binding HS). Our results suggest that the bio-
synthesis of HSact and the gD-binding HS is regulated by
several enzymes. The newly identified enzyme provides an
additional tool for both understanding the mechanism for the
biosynthesis of the biologically active HS and for investigating
the relationship between the saccharide sequences and the
biological functions of HS.
EXPERIMENTAL PROCEDURES
Materials
Recombinant human 3-OST-3A and mouse 3-OST-1 enzymes were
expressed in Sf9 cells using a baculovirus expression system. The
enzymes were purified by heparin-Toyopearl and 3,5-ADP-agarose
chromatographies as described previously (11, 21). [35S]PAPS was pre-
pared by incubating 0.4 to 2 mCi/ml [35S]Na2SO4 (carrier-free, ICN) and
16 mM ATP with 5 mg/ml dialyzed yeast extract (Sigma) (12). HS was
either isolated from 33-cells, an L-cell variant, or from Chinese hamster
ovary (CHO) cells as described previously (12). The concentrations of
the unlabeled HS were determined by a method reported by Björnsson
(22). Preparation of metabolically 35S-labeled HS from CHO cells was
described elsewhere (23). Human AT is from Cutter Biological (Berke-
ley, CA). A truncated form of herpes simplex virus, type 1, glycoprotein
D, gD-1(306t), and monoclonal anti-gD (DL6) were generous gifts of
Drs. Cohen and Eisenberg of the University of Pennsylvania (24). The
3H-labeled disaccharide standards, GlcUA-AnMan3S6S and IdoUA2S-
AnMan6S, were prepared from 3H-labeled HS (gifts from Dr. Rosen-
berg, Massachusetts Institute of Technology) (25). The 35S-labeled dis-
accharide standards, IdoUA2S-AnMan3S and IdoUA2S-AnMan3S6S,
were prepared from low pH (pH 1.5) nitrous acid-degraded HS that was
modified by purified 3-OST-3 enzyme as described by Liu et al. (11).
Isolation of 3-OST-5 cDNA
GenBankTM data base was probed with the amino acid sequence of
3-OST-1 using tBlastn. By using Genscan, we predicted a 1,041-bp open
reading frame that encodes a homologous protein from a genomic clone
RP11-112L15 with GenBankTM accession number AL355498. The open
reading frame sequence, designated as 3-OST-5, was located in two
exons. Both 5- and 3-primers were synthesized based upon the se-
quence of exon 1 and exon 2, respectively. The following are the se-
quences of the two specific primers: 5- GGAGGGCC ATG CTA TTC
AAA CAG-3 (5-primer), and 5-TTA GGG CCA GTT CAA TGT CCT-3
(3-primer). We cloned the cDNA using PCR from a human placenta
cDNA library with the two specific primers. The resultant PCR product
(about 1.0 kb) was inserted into the pGEM-T-easy vector (pGEM-T-
3OST5) and sequenced for both strands. The isolated cDNA has an
identical sequence that was predicted from the genomic clone. 5-Rapid
amplification of cDNA ends was performed but failed.
Cell Culture
Both COS-7 and wild type CHO cells were from Dr. R. Jude Samulski
(University of North Carolina). COS-7 cells and CHO cells were main-
tained in logarithmic growth by subculturing biweekly at 37 °C under
6% CO2 humidified atmosphere. COS-7 cells and CHO cells were grown
in Dulbecco’s modified Eagle’s medium (Invitrogen) and in F-12 me-
dium (Invitrogen) supplemented with 10% fetal bovine serum (JRH
Biosciences), respectively.
Expression of 3-OST-5
3-OST-5 expression plasmid was constructed by inserting the open
reading frame of 3-OST-5 into a pcDNA3.1 (Invitrogen) expression
vector. The open reading frame was obtained by reamplifying the se-
quence from pGEM-T-3OST5 by PCR using the following primers: 1)
the 5-specific primer, 5-TCA AAGCTT GCCACC ATG CTATTCAAA-
CAGCA-3, contains an HindIII site (underlined), the consensus Kozak
sequence (italicized) and a start codon; and 2) the 3-specific primer,
5-GC TCTAGA TTAGGGCCAGTTCAATGTCCT-3, contains an XbaI
site (underlined). PCRs were carried out using Advantage-2 PCR kit
(CLONTECH) with the initial denaturation for 2 min at 94 °C, followed
by 30 cycles of a reaction consisting of 45 s for denaturation at 94 °C,
45 s for annealing at 62 °C, and 90 s for elongation at 72 °C. The PCR
fragment was subcloned into pcDNA3.1 (Invitrogen) using HindIII/
XbaI sites. The coding region of the construct was completely sequenced
on both strands, and the construct was designated pcDNA3.1-3OST5.
pcDNA3.1-3OST5 or pcDNA3 plasmid was transfected into exponen-
tially growing COS-7 cells using LipofectAMINE 2000 (Invitrogen).
Measurement of 3-OST-5 Activity
Preparation of [35S]HS—The crude enzyme was extracted from
transfected COS-7 cells. The cells were harvested 72 h after transfec-
tion. Approximately 3  106 cells were mixed with 100 l of cold 0.25 M
sucrose containing 1% Triton X-100 (v/v) and incubated on ice for 30
min. The insoluble residues were removed after centrifuging at
10,000  g for 10 min. The HS sulfotransferase activity was determined
by incubating 40 g of cell extract with 1 g of unlabeled HS (from
2 Human 3-OST-3A and 3-OST-3B have nearly identical amino acid
sequences in the proposed sulfotransferase domain. Both enzymes sul-
fate identical disaccharides and have the activity in assisting HSV-1
entry. For clarity, we used 3-OST-3 to represent both 3-OST-3A and
3-OST-3B unless specified otherwise.
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33-cells), 4  107 cpm of [35S]PAPS, in 50 l of a buffer containing 50
mM MES, 10 mM MnCl2, 5 mM MgCl2 and 1% Triton X-100 (pH 7). The
reaction was incubated at 37 °C for 2 h, quenched by heating at 100 °C
for 1 min, and centrifuged at 10,000  g for 1 min to remove insoluble
materials. The sample was then subjected to a 200-l DEAE-Sepharose
column to purify [35S]HS (12).
Disaccharide Analysis of [35S]HS—The [35S]HS modified by 3-OST-5
was mixed with 20 g of unlabeled HS (from ICN) and degraded with
nitrous acid at pH 1.5 followed by reduction with sodium borohydride
(26). The resultant 35S-labeled disaccharides were mixed with a 3H-
labeled disaccharide standard, IdoUA2S-[1-3H]AnMan6S, and desalted
on a Bio-Gel P-2 column (0.75  200 cm) that was equilibrated with 0.1
M ammonium bicarbonate at a flow rate of 4 ml/h. The 3H-labeled
disaccharide standard was used to locate the elution position of the
disaccharides from the Bio-Gel P-2 column.
The disaccharides were resolved by a C18-reversed phase column
(0.46  25 cm) (Vydac) under the reverse-phase ion-pairing HPLC
(RPIP-HPLC) condition (11). Briefly, the column was eluted with ace-
tonitrile as follows: 8% for 30 min followed by 15% for 15 min and
followed by 19.5%, in a solution containing 38 mM ammonium phos-
phate monobasic, 2 mM phosphoric acid, and 1 mM tetrabutylammo-
nium phosphate monobasic (Fluka) at a flow rate of 0.5 ml/min.
Characterization of 3-OST-5-modified HS
Preparation of 3-OST-1 and 3-OST-3-modified HS—To prepare
3-OST-3-modified HS, HS (1 g from 33-cells) was mixed with 30 ng of
purified 3-OST-3A enzyme and [35S]PAPS (4  107 cpm) in a buffer
containing 50 mM MES, 1% Triton X-100, 1 mM MgCl2, 2 mM MnCl2, 150
mM NaCl, and 168 g/ml bovine serum albumin (pH 7), in a final
volume of 50 l. The reaction was incubated at 37 °C for 2 h and was
then heated at 100 °C for 2 min. The resultant product was centrifuged
at 14,000 rpm for 1 min to remove insoluble materials. The supernatant
was loaded onto a 200 l DEAE-Sepharose column, and the [35S]HS was
eluted from the column with 1000 mM NaCl (12). To prepare 3-OST-1-
modified HS, we utilized 70 ng of purified enzyme and followed nearly
identical procedures except for omitting the 150 mM NaCl.
Demonstration of 3-OST-5-modified HS Binding to AT—The binding
of the 3-OST-5-modified HS to AT was determined using an AT/con-
canavalin A (ConA)-Sepharose approach (12). Briefly, HS (10,000–
100,000 cpm) was incubated in 150 l of a buffer, which contains 10 mM
Tris-HCl, 150 mM NaCl, 1 M dextran sulfate, 1 mM Ca2, Mg2, and
Mn2, and 0.1 mg/ml AT (pH 7.5), at room temperature for 30 min. The
solution was mixed with the prewashed ConA-Sepharose (60 l of 1:1
slurry) and agitated at room temperature for 1 h. The gel was then
washed with 3  1 ml of a buffer containing 10 mM Tris-HCl, 0.0004%
Triton X-100, and 150 mM NaCl (pH 7.5). The HS was eluted from the
gel by 1 ml of a buffer containing 10 mM Tris-HCl, 1000 mM NaCl, and
0.0004% Triton X-100 (pH 7.5).
Determination of the Binding of 3-OST-5-modified HS to gD—The
assay for determining the binding of 3-O-sulfated HS to gD was carried
out by an immunoprecipitation procedure using anti-gD monoclonal
antibody (13). The enzyme-modified HS (100,000–200,000 cpm) was
incubated in 50 l of a buffer containing 50 mM Tris-HCl, 150 mM NaCl,
and 0.01% Triton (pH 7) (binding buffer), and 2 mg/ml of gD at room
temperature for 30 min. The anti-gD monoclonal antibody DL6 (5 l)
was added and incubated at 4 °C for 1 h followed by the addition of
protein A-agarose gel (80 l of 1:1 slurry) and agitated at 4 °C for an
additional hour. The HS was eluted from the gel with 1 ml of 1000 mM
NaCl in the binding buffer.
Determination of HSact Conversion Activity—The assay was specifi-
cally designed to determine the HS biosynthetic activity that generates
HSact (12). Briefly, cell extract was incubated with metabolically 35S-
labeled nonanticoagulant HS (from wild type CHO cells) and unlabeled
PAPS. The resultant [35S]HS was subjected to the AT-binding assay as
described above. The increase in the percentage of the [35S]HS that
binds to AT correlated to the amount of HSact conversion activity in the
cell extract.
Herpes Simplex Viral Entry Assay
The conditions for growing cells and different HSV strains were
described previously (13). The viral infectivity assay is based on visu-
alization of the cells carrying -galactosidase activity (25). CHO cells
were transfected in 6-well dishes, using LipofectAMINE (Invitrogen)
with pcDNA3.1–3OST5 plasmid or control plasmid (pcDNA3) at 1.5–2.0
g per well in 1 ml. At about 36 h post-transfection, cells were exposed
to recombinant HSV-1 (HSV-1(KOS)gL86) (a gift from Dr. Spear,
Northwestern University) that expresses -galactosidase upon viral
entry. At 6 h post-infection, the cells were fixed in PBS containing 2%
formaldehyde and 0.2% glutaraldehyde, permeabilized in 2 mM MgCl2
containing 0.01% deoxycholate and 0.02% Nonidet P-40, and incubated
with buffered X-gal (0.5 mg/ml). Three hours later the infected cells
were visible in blue due to the action of -galactosidase on X-gal. The
transfection efficiency for CHO cells was determined by transfecting a
plasmid expressing -galactosidase as a reporter gene.
Northern Blot Analysis
The coding sequence of 3-OST-5 was labeled with [-32P]dCTP in a
reaction with Klenow enzyme (Roche Molecular Biochemicals) and used
as a probe to hybridize the Human Multiple Tissue Northern (MTN)
blot (CLONTECH). The hybridization was carried out in ExpressHyb
Hybridization Solution (CLONTECH) at 60 °C for 1 h, and the blot was
washed with 0.1 SSC containing 0.5% SDS at 60 °C for 40 min (where
1 SSC contains 150 mM NaCl and 15 mM sodium citrate, pH 7.0). The
membrane was exposed to an x-ray film for 4 days.
RESULTS
Isolation of the cDNA Encoding 3-OST-5—Probing the non-
redundant data base of National Center for Biotechnology In-
formation with the deduced amino acid sequence of human
3-OST-1 (accession number AF033827), we identified a 165-kb
genomic clone with GenBankTM accession number AL355498.
An open reading frame was found to be 1041 bp. The predicted
open reading frame was located in two exons that were gapped
by a 4.5-kb intron. The open reading frame of this protein,
assigned as 3-OST-5, was amplified from a human placenta
cDNA library using specific 5- and 3-primers as described
under “Experimental Procedures.” 3-OST-5 cDNA sequence
and the predicted amino acid sequence are shown in Fig. 1. We
attempted to obtain further upstream 3-OST-5 sequence by
using 5-rapid amplification of cDNA ends but failed. The iso-
lated 3-OST-5 cDNA contains 1041 bp, and the deduced peptide
of 346 amino acid residues predicts a type II membrane-bound
protein. The protein has four potential N-glycosylation sites
with the predicted molecular mass of 40,407 Da. The deduced
amino acid sequence of 3-OST-5 has 71 and 58% homology to
3-OST-1 and 3-OST-3 in the sulfotransferase domains, respec-
tively (Fig. 2). Putative PAPS-binding sites were also found in
3-OST-5 based upon the PAPS-binding consensus sequences
(27, 28) (Fig. 2). The genomic BAC clone RP11-112L15, which
contains 3-OST-5 gene, was annotated to be mapped on human
chromosome 11q22.2. Alignment of the genomic sequence with
3-OST-5 cDNA revealed that exon 1 and exon 2 contain 107 and
934 bp of the open reading frame, respectively.
Determination of the 35S-Labeled Sulfation Site of 3-OST-5-
modified HS—Because the cloned 3-OST-5 has high homology
to 3-OST-1 and 3-OST-3, we tested the hypothesis for 3-OST
activity. The plasmid expressing 3-OST-5 was transiently
transfected into exponentially growing COS-7 cells. The cells
were solubilized with detergent. HS sulfotransferase activity
was determined by incubating with unlabeled HS and
[35S]PAPS as described under “Experimental Procedures.” The
resultant [35S]HS was subjected to nitrous acid degradation at
pH 1.5 followed by sodium borohydride reduction to prepare
35S-labeled disaccharides. This approach has been employed to
successfully characterize the sulfation sites of 3-OST-2 and
3-OST-3 (8, 13).
The 35S-labeled disaccharides were resolved on RPIP-HPLC,
and the chromatograms are shown in Fig. 3. Comparing the
profiles of the degraded [35S]HS that was modified by
pcDNA3-transfected cells (Fig. 3A), we found additional 35S-
labeled disaccharides in the 3-OST-5-modified HS (Fig. 3B). By
co-eluting with the appropriate disaccharide standards on
RPIP-HPLC, we identified that three of the 35S-labeled disac-
charides were 3-O-sulfated disaccharides with the structures of
IdoUA2S-AnMan3S (eluted at 38.5 min), GlcUA-AnMan3S6S
(eluted at 55.5 min), and IdoUA2S-AnMan3S6S (eluted at 70.3
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min). A small peak of 35S-labeled disaccharide with a structure
of IdoUA2S-AnMan6S was also observed (eluted at 59.6 min).
The IdoUA2S-AnMan6S was observed in HS modified with
pcDNA3-transfected COS-7 cells (data not shown), although
the level of this disaccharide varied between experiments. The
presence of IdoUA2S-AnMan6S, which is a common disaccha-
ride in HS, was unlikely to be associated with the activity of
3-OST-5. We also detected a minor 35S-labeled peak at 48 min.
The identity of this 35S-labeled peak was unknown. Taken
together, these results suggest that the expressed 3-OST-5 has
the anticipated 3-OST activity. It is important to note that
IdoUA2S-AnMan3S and IdoUA2S-AnMan3S6S are character-
istic disaccharides of 3-OST-3-modified HS (13), whereas
GlcUA-AnMan3S6S is a characteristic disaccharide of 3-OST-
1-modified HS (12).
The Activity of 3-OST-5 in Assisting HSV-1 Entry—A previ-
ous study (13) demonstrated that 3-OST-3-modified HS serves
as a receptor for herpes simplex virus, type 1, entry. Because
we detected the disaccharides of 3-OST-3-modified HS, it ap-
peared logical that 3-OST-5-modified HS might also generate
an entry receptor for HSV-1. Therefore, we decided to test this
possibility using an approach that was previously published
(13). A recombinant -galactosidase-expressing HSV-1 strain
(HSV-1(KOS)gL86) was used for the entry assay. This recom-
binant virus expresses -galactosidase from an insert in the
viral genome immediately upon entry into cells. As shown in
Fig. 4A, the mock-transfected CHO cells are resistant to HSV-1
entry (no dark cells) as reported previously (29). In contrast,
a significant number of CHO cells transfected with
pcDNA3.1–3OST5 were rendered susceptible (Fig. 4B, dark
cells) to the entry of HSV-1. We estimated that about 20% of the
cells were susceptible to HSV-1 infection, which coincided with
the transfection efficiency. In separate sets of experiments, we
also found that 3-OST-5-modified HS does not generate recep-
tors for other alphaherpesviruses. The viruses examined for
entry via 3-OST-5-modified HS included wild type HSV-2,
HSV-1 Rid mutants (24), bovine herpesvirus, and pseudorabies
virus (data not shown).
Furthermore, we examined whether 3-OST-5-modified HS
bound to gD. The results showed that 3-OST-5-modified HS has
about a 2-fold increase in the binding to gD compared with the
control, suggesting that 3-OST-5-modified HS generates gD-
binding sites (Table I). We noted that the gD-binding percent-
age of 3-OST-5-modified HS (9.0%) was less than that of 3-OST-
3-modified HS (23.1%). Such deviation is likely due to the fact
the 3-OST-5 enzyme was in a mixture containing other HS
FIG. 1. The nucleotide and deduced amino acid sequences of 3-OST-5 (GenBankTM accession AF503292). The single predicted
membrane spanning domain and four potential N-linked glycosylation sites are indicated by the doubled underline and by the underlines with a
 below the glycosylated Asn, respectively.
FIG. 2. Multiple amino acid sequence alignment of human 3-OST-5 with human 3-OST-1, 3-OST-3A, and 3-OST-3B. The alignment was
performed by using the program BioEdit. Introduced gaps are shown as hyphens, and aligned amino acids are boxed and shaded with black for
identical residuals and dark gray for similar residuals. 5-PSB represents the putative domain that binds to 5-phosphate of PAPS, and 3-PSB
represents the putative domain that binds to 3-phosphate of PAPS.
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sulfotransferases, whereas purified 3-OST-3A enzyme was em-
ployed to prepare 3-OST-3-modified HS. Taken together, our
results suggest that 3-OST-5 is capable of assisting the entry of
HSV-1 by generating a receptor for gD. In addition, it is appar-
ent that the mechanism for 3-OST-5-assisted HSV-1 infection
is very similar to what was previously characterized for
3-OST-3. However, we could not conclude whether or not the
saccharide sequences of the gD-binding site in 3-OST-5-modi-
fied HS and the sequence in 3-OST-3A-modified HS were
identical.
Demonstration of 3-OST-5-modified HS Binding to AT—
From the result of the disaccharide analysis of 3-OST-5-modi-
fied HS as described above, we found that 3-OST-5-modified
HS also contains GlcUA-AnMan3S6S. This observation
prompted us to determine whether or not 3-OST-5-modified HS
bound to AT. The results for the binding of [35S]HS to AT are
shown in Table I. As expected, 37.0% of 3-OST-1-modified HS
bound to AT, whereas only 1.4% of 3-OST-3-modified HS bound
to AT. Those results were consistent with the previous reports
(8, 12). Comparing the percentages of HSact between 3-OST-5-
modified HS and control, we found that the binding of 3-OST-
5-modified HS to AT was 6.3-fold higher than the control sam-
ple. The result suggests that 3-OST-5-modified HS binds to AT.
The conclusion was further strengthened by the results as
presented below.
We also determined the HSact conversion activity of the cell
extract from 3-OST-5-transfected cells, as this assay was spe-
cifically designed to measure the enzymatic activity that gen-
erates anticoagulant HS (12). We incubated nonanticoagulant
[35S]HS with cell extract and unlabeled PAPS. The resultant
[35S]HS was subjected to AT/ConA-affinity gel. We found that
about 4.8% of the [35S]HS bound to AT/ConA-affinity gel after
incubation with 3-OST-5-transfected cell extract, whereas only
0.12% of the [35S]HS bound to AT/ConA-affinity gel after incu-
bation with the control cell extract (transfected with pcDNA3).
Our results demonstrated that the HSact conversion activity in
3-OST-5-transfected cells was elevated by 40-fold. The data
were consistent with the conclusion that 3-OST-5 has the ac-
tivity in synthesizing HSact.
We compared the composition of the 35S-labeled disacchar-
ides from 3-OST-5-modified HSact and from 3-OST-5-modified
HSinact (nonantithrombin-binding HS). The HSinact and HSact
were separated by the AT/ConA-affinity approach as described
under “Experimental Procedures.” Nearly 35% of 3-OST-5-
modified HSact bound to AT-affinity gel (Table I), suggesting
that the fractionation had significantly enriched HSact. Both
the HSinact and HSact were degraded with nitrous acid at pH
1.5 followed by sodium borohydride reduction, and the result-
ant 35S-labeled disaccharides were analyzed by RPIP-HPLC
(Fig. 5). As shown in Fig. 5B, 35S-labeled GlcUA-AnMan3S6S
was the major disaccharide in the 3-OST-5-modified HSact. It is
noteworthy that GlcUA-AnMan3S6S is a characteristic disac-
charide of 3-OST-1-modified HS and is part of the AT-binding
site (12). We also noted that GlcUA-AnMan3S6S was still ob-
served in HSinact. Two possible reasons might contribute to this
FIG. 3. RPIP-HPLC chromatograms of the disaccharide anal-
ysis of 3-OST-5-modified HS. Cell extracts from COS-7 cells trans-
fected with the empty plasmid vector pcDNA 3 (A) or with the plasmid
expressing 3-OST-5 (B) were incubated with unlabeled HS and
[35S]PAPS to prepare the [35S]HS. The resultant [35S]HS was depolym-
erized by nitrous acid at pH 1.5 followed by sodium borohydride reduc-
tion. The resultant 35S-labeled disaccharides were resolved on RPIP-
HPLC. The elution positions of the disaccharide standards are
indicated by arrows, where arrow 1 represents IdoUA2S-AnMan3S;
arrow 2 represents GlcUA-AnMan3S6S; arrow 3 represents IdoUA2S-
AnMan6S; and arrow 4 represents IdoUA2S-AnMan3S6S.
FIG. 4. Entry of HSV-1 into CHO-K1 cells and transfected
CHO-K1 cells. CHO-K1 cells were transfected with control plasmid (A)
or with pcDNA3.1–3OST5 (B). At 36 h after transfection, the cells were
exposed to KOS-gL86 at 100 plaque-forming units/cell. Six hours later,
the cells were washed, fixed, and incubated with X-gal to identify
infected cells (dark cells).
TABLE I
The binding of 3-OST-5-modified HS to gD and AT
Binding to gDa (%) Binding to ATb (%)
Controlc 5.0  0.4 (n  2) 0.68  0.24 (n  4)
3-OST-5
modified HS
9.0  0.1 (n  2) 4.3  1.8 (n  4)
3-OST-5
modified HSactd
Not determined 34.7 (n  1)
3-OST-1
modified HSe
6.6  0.3 (n  2) 37.0  3.3 (n  4)
3-OST-3
modified HSe
23.1  3 (n  2) 1.4  0.7 (n  4)
a The binding of the HS and gD was determined by incubating mod-
ified [35S]HS with gD followed by immunoprecipitation using anti-gD
monoclonal antibody (DL6) to precipitate the complex of [35S]HS and
gD. Data are presented as the mean  S.D., where n represents the
number of determinations.
b The binding of the HS to AT was determined by incubating modified
[35S]HS and AT by using AT/ConA-Sepharose gel as described under
“Experimental Procedures.”
c Control was the [35S]HS that was prepared by incubating HS with
the cell extract transfected with pcDNA3.
d 3-OST-5-modified HSact was prepared by AT-affinity fraction-
ation from 3-OST-5-modified HS as described under “Experimental
Procedures.”
e 3-OST-1- and 3-OST-3-modified HS were prepared by incubating
unlabeled HS (from 33 cells), [35S]PAPS, and purified 3-OST-1 (70 ng)
and 3-OST-3 (35 ng), respectively.
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observation. First, the AT-affinity fractionation was incom-
plete. Second, it is known that HSinact contains GlcUA-
AnMan3S6S (12). Taken together, our results demonstrated
that 3-OST-5 enzyme generated an AT-binding site, and the
HSact contained the disaccharide, GlcUA-AnMan3S6S. In con-
clusion, our results indicated that 3-OST-5 synthesized both
HSact and gD-binding HS (8).
Of particular interesting is that two 35S-labeled disacchar-
ides, IdoUA2S-AnMan3S and IdoUA2S-AnMan3S6S, were
absent in 3-OST-5-modified HSact (Fig. 5B). Those two disac-
charides are believed to be parts of the gD-binding site in
3-OST-5-modified HS, which contribute to the activity in
assisting HSV-1 entry. The data suggested that 3-OST-5 enzyme
sulfates two subpopulations of HS substrates. One population is
HSact precursor, which becomes HSact after 3-OST-5 modifica-
tion. Another population is gD-binding HS precursor, which be-
comes gD-binding HS after 3-OST-5 modification. The data sup-
ported the conclusion from the previous reports (23, 30), which
demonstrated that the biosynthesis of HSact is regulated by the
availability of the HSact precursors for 3-O-sulfation.
Tissue Distribution of 3-OST-5—Northern analysis was car-
ried out on a human Northern multiple tissue blot using
3-OST-5 open reading frame as a probe. It appears that
3-OST-5 is predominantly expressed in skeletal muscle with a
size of 2.4 and 3.8 kb (Fig. 6, top panel). The distribution of
3-OST-5 is distinct from those of 3-OST-1 and 3-OST-3A and
3-OST-3B as reported by Shworak and colleagues (28).
DISCUSSION
HS is composed of sulfated glucosamine and glucuronic/idu-
ronic acid residues. The 3-O-sulfated glucosamine is a rare
constituent in the HS from natural sources and plays critical
roles in binding to AT (31), herpes simplex virus, type 1, enve-
lope protein gD (13), growth factor receptor (32), and fibroblast
growth factor 7 (33). Although we know that the saccharide
sequences of the gD-binding site and AT-binding sites are
distinct (13), it still remains to be investigated whether or not
the sequences for the bindings of fibroblast growth factor 7 and
fibroblast growth factor receptor are identical to the AT-bind-
ing site. The 3-O-sulfated glucosamine residue is biosynthe-
sized by 3-OST. At least five different isoforms of 3-OST
isoforms have been identified (34). The characteristic
disaccharides of the 3-OST-modified HS and the biological
functions of the modified HS are summarized in Table II.
In this study, we report a new member of 3-OST family.
From our data, we were unable to conclude that the ATG of
3-OST-5 represents the genuine initiation codon because we
did not obtain a further 5-upstream cDNA sequence. It should
be noted that 5-untranslated regions play an important role in
determining the translational efficiency of heparan sulfate
N-deacetylase/N-sulfotransferase isoforms in different tissues
(35). Nevertheless, the isolated 3-OST-5 contains a transmem-
brane domain, which predicts a type II membrane-bound pro-
tein, and a functional sulfotransferase domain. Those domains
are found in the previously characterized full-length 3-OST-2
and 3-OST-3 (28), although the full-length 3-OST-1 lacks trans-
membrane domain (14). If an additional sequence were present
in 3-OST-5 coding region, we would expect that it would encode
an additional cytosolic domain. It is known that the cytosolic
domains of previously characterized 3-OST do not to contribute
to the enzymatic activities3 (11, 14).
Amino acid homology search revealed that 3-OST-5 has 58%
homology to 3-OST-3 and 72% homology to 3-OST-1, respec-
tively, in the predicted sulfotransferase domain. The data sug-
gest that the amino acid sequence of 3-OST-5 is closer to
3-OST-1. However, we failed to identify a domain in 3-OST-5
that is specifically homologous to 3-OST-1 or to 3-OST-3, im-
plying that the substrate specificities of 3-OST isoforms are
3 A truncated 3-OST-3A maintains its activity by removing its intra-
cellular and transmembrane domains. 3-OST-1 enzyme that was orig-
inally purified from L-cell media was a truncated form, which lacks the
first 20 amino acid residues from the N terminus.
FIG. 5. RPIP-HPLC chromatograms of the disaccharide anal-
ysis of 3-OST-5-modified HSinact and HSact. HSact was prepared
from 3-OST-5-modified HS using an AT-affinity column. HSinact was the
fraction that does not bind to AT-affinity column. HSact was eluted from
the AT-affinity column with 1 M NaCl. Both HSinact and HSact were
degraded with nitrous acid (pH 1.5) followed by sodium borohydride
reduction. The arrows indicate the elution positions of disaccharide
standards as described in Fig. 3.
FIG. 6. Expression of 3-OST mRNA in human tissues. A human
multiple tissue Northern blot was hybridized with human 3-OST-5
(upper panel) and -actin (lower panel) cDNA probes labeled with
[32P]dCTP under the conditions described under “Experimental
Procedures.”
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determined by the three-dimensional structures of the en-
zymes. We noted that 3-OST-1 is a secreted protein because it
lacks a transmembrane domain (14), whereas 3-OST-5 is likely
a membrane-bound protein with a predicted transmembrane
domain. Indeed, we failed to detect 3-OST-5 activity in the
media.4 A recent report (36) demonstrated that the transmem-
brane domain of the 3-OST had no effect on their substrate
specificities. Based upon their results, we concluded that the
additional transmembrane domain of 3-OST-5 is unlikely to
provide profound effect on the activities in synthesizing HSact
and gD-binding HS.
The substrate specificity of 3-OST-5 was characterized by
determining the identities of the 35S-labeled disaccharides
from low pH nitrous acid-degraded 3-OST-5-modified HS. We
found that the enzyme generates at least three 3-O-sulfated
disaccharides as follows: IdoUA2S-AnMan3S, GlcUA-
AnMan3S6S, and IdoUA2S-AnMan3S6S.5 Among these disac-
charides, IdoUA2S-AnMan3S and IdoUA2S-AnMan3S6S are
the characteristic disaccharides of 3-OST-3-modified HS,
whereas GlcUA-AnMan3S6S is a characteristic disaccharide of
3-OST-1-modified HS (11, 12). Thus, we concluded that
3-OST-5 possesses both the activities of 3-OST-1 and 3-OST-3.
It is known that 3-OST-1 generates HSact, whereas 3-OST-3
generates entry receptor for HSV-1 (12, 13). As expected,
3-OST-5-modified HS binds to AT and gD. In addition, trans-
fection of the plasmid expressing 3-OST-5 rendered the suscep-
tibility of HSV-1 to wild type CHO cells. Because both
3-O-sulfated glucosamine N-sulfate (GlcNS3S6S) and 3-O-
sulfated N-unsubstituted glucosamine (GlcNH23S6S) are
susceptible to low pH nitrous acid degradation (8), we could not
conclude whether or not 3-OST-5 sulfates N-unsubstituted glu-
cosamine or N-sulfated glucosamine. Such a conclusion will
become possible when a purified 3-OST-5 enzyme is available.
Regardless of the limitations in the disaccharide analysis, our
results indicate that 3-OST-5 has both 3-OST-1- and 3-OST-3-
activities. It should be noted that two additional isoforms of
3-OST, 3-OST-2 and 3-OST-4, were reported (28). It is known
that 3-OST-2 does not generate HSact (8).
Our Northern analysis suggests that 3-OST-5 is predomi-
nantly expressed in the human skeletal muscle tissue. A pre-
vious report demonstrated that 3-OST-1 and 3-OST-3 (includ-
ing 3-OST-3A and 3-OST-3B) were widely expressed in
numerous human tissues, but low in skeletal muscle (28). The
tissue distribution of 3-OST-5 suggests that 3-OST-5-modified
HS may provide a unique biological function in this tissue. It is
very interesting to note that a unique subset of HS was iden-
tified in human skeletal muscle tissues by a set of antibodies
that bind to HS (37). An elegant study was recently published
(38) to determine the binding sequences of these antibodies.
However, it still remains to be investigated whether or not the
unique subset of HS found in the skeletal muscle tissue is
associated with 3-OST-5 modification.
Clinical manifestations of herpes simplex virus are typically
seen in two types of cells as follows: mucosal epithelium with
characteristic herpetic lesions, and in a few cases, neuronal
cells, causing life-threatening encephalitis. Acute viremia ex-
ists but is very rarely seen in infected patients. Based on the
current knowledge, it is unlikely that infection of HSV in skel-
etal muscle has long term pathogenic effects. It is very inter-
esting to note that recent studies (39, 40) show that herpes
simplex virus, type 1, can be utilized as a viral vector to deliver
genes to the human skeletal muscle. For example, a specially
engineered herpes simplex virus 1 was used for Duchenne
muscular dystrophy (39). The advantages for using herpes sim-
plex virus, type 1, vector include high transduction efficiency
and the capability to pack a large gene (40). Given the facts
that 3-OST-5-modified HS serves as an entry receptor for
HSV-1 and it is expressed in the human skeletal muscle, it is
possible that the 3-OST-5-modified HS could serve as a recep-
tor in skeletal muscle tissues for HSV-1 infection. If this is the
case, further investigation of the mechanism for the 3-OST-5-
assisted HSV-1 entry will be beneficial for not only understand-
ing/modulating the pathogenic effects of the virus but also for
its improved use as an important gene therapy vector for treat-
ing muscular dystrophy.
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